All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) stage III (locally advanced) stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
melanoma (ML), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMspire-150 (BRAF mutant), 2020 0.85 [0.65; 1.12]
IMspire-170, 2020 1.06 [0.69; 1.62]
0.91 [0.72 ; 1.14 ] IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020 2 0% 960 low not evaluable progression or deaths (PFS)detailed results IMspire-150 (BRAF mutant), 2020 0.78 [0.63; 0.97]
IMspire-170, 2020 1.15 [0.88; 1.50]
0.94 [0.64 ; 1.37 ] IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020 2 80% 960 low not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable objective responses (ORR)detailed results IMspire-150 (BRAF mutant), 2020 1.19 [0.83; 1.71]
IMspire-170, 2020 0.77 [0.50; 1.17]
0.97 [0.63 ; 1.49 ] IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020 2 58% 960 low not evaluable AE (any grade)detailed results IMspire-170, 2020 14.27 [3.34; 61.03]
14.27 [3.34 ; 61.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 4.03 [2.70; 6.00]
4.03 [2.70 ; 6.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-150 (BRAF mutant), 2020 1.23 [0.42; 3.56]
IMspire-170, 2020 1.39 [0.43; 4.44]
1.30 [0.59 ; 2.84 ] IMspire-150 (BRAF mutant), 2020, IMspire-170, 2020 2 0% 947 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMspire-150 (BRAF mutant), 2020 0.78 [0.47; 1.29]
0.78 [0.47 ; 1.29 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable STRAE (any grade)detailed results IMspire-150 (BRAF mutant), 2020 1.24 [0.85; 1.81]
1.24 [0.85 ; 1.81 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable TRAE (any grade)detailed results IMspire-150 (BRAF mutant), 2020 0.82 [0.11; 5.85]
0.82 [0.11 ; 5.85 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.41 [0.93; 2.12]
1.41 [0.93 ; 2.12 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.44 [0.48; 4.34]
1.44 [0.48 ; 4.34 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.47 [0.45; 13.60]
2.47 [0.45 ; 13.60 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Chorioretinopathy TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.61 [0.02; 18.27]
0.61 [0.02 ; 18.27 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.30 [0.01; 6.77]
0.30 [0.01 ; 6.77 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.53 [0.16; 1.76]
0.53 [0.16 ; 1.76 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Dry skin TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Erythema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 7.41 [0.37; 148.78]
7.41 [0.37 ; 148.78 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 3.70 [0.38; 35.82]
3.70 [0.38 ; 35.82 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.99 [0.64; 1.52]
0.99 [0.64 ; 1.52 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.36 [0.78; 2.37]
1.36 [0.78 ; 2.37 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
2.46 [0.22 ; 27.26 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.17 [0.02; 1.40]
0.17 [0.02 ; 1.40 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 4.92 [0.22; 109.67]
4.92 [0.22 ; 109.67 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 2.46 [0.22; 27.26]
2.46 [0.22 ; 27.26 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.24; 6.13]
1.22 [0.24 ; 6.13 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Rash TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.98 [0.53; 1.81]
0.98 [0.53 ; 1.81 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 0.48 [0.09; 2.52]
0.48 [0.09 ; 2.52 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.14; 7.03]
0.98 [0.14 ; 7.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results Out of scale IMspire-170, 2020 22.68 [1.32; 388.47]
22.68 [1.32 ; 388.47 ] IMspire-170, 2020 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 4.44 [1.47; 13.42]
4.44 [1.47 ; 13.42 ] IMspire-170, 2020 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 1.65 [0.39; 7.00]
1.65 [0.39 ; 7.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 1.77 [0.73; 4.30]
1.77 [0.73 ; 4.30 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMspire-150 (BRAF mutant), 2020 1.22 [0.02; 61.84]
1.22 [0.02 ; 61.84 ] IMspire-150 (BRAF mutant), 2020 1 0% 511 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 3.00 [0.60; 15.03]
3.00 [0.60 ; 15.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 1.99 [0.49; 8.06]
1.99 [0.49 ; 8.06 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 2.00 [0.59; 6.74]
2.00 [0.59 ; 6.74 ] IMspire-170, 2020 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 10.02 [0.54; 184.60]
10.02 [0.54 ; 184.60 ] IMspire-170, 2020 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.06; 15.80]
0.98 [0.06 ; 15.80 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 6.03 [0.72; 50.50]
6.03 [0.72 ; 50.50 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 7.83 [1.77; 34.66]
7.83 [1.77 ; 34.66 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 7.98 [0.42; 151.89]
7.98 [0.42 ; 151.89 ] IMspire-170, 2020 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 12.08 [0.67; 217.70]
12.08 [0.67 ; 217.70 ] IMspire-170, 2020 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 2.49 [0.48; 12.97]
2.49 [0.48 ; 12.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 17:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866